NOC2L联合SLFN11检测在肝癌病情及预后评估中的临床价值  

Clinical value of NOC2L combined with SLFN11 detection in theevaluation of liver cancer condition and prognosis

作　　者：何建新[1] 张洪彬[2] 楼韵燕 HE Jianxin;ZHANG Hongbin;LOU Yunyan(Department of Laboratory Medicine,Yiwu Central Hospital,Yiwu,Zhejiang 322000,China;不详)

机构地区：[1]义乌市中心医院检验科,浙江义乌322000 [2]义乌市中心医院放射科

出　　处：《中华全科医学》2025年第5期823-826,共4页Chinese Journal of General Practice

基　　金：浙江省医药卫生科技计划项目(2024KY507)。

摘　　要：目的 NOC2L和SLFN11与恶性肿瘤发病机制密切相关,本研究旨在分析NOC2L联合SLFN11检测在肝癌中的临床价值。方法 检测2020年1月—2021年12月义乌市中心医院诊治的95例肝癌患者(HCC组)及51例肝脏良性疾病患者(对照组)NOC2L、SLFN11表达水平,并分析与预后、生存期的关系。结果 HCC组肿瘤组织NOC2L高于癌旁组织和对照组(1.26±0.25 vs.0.72±0.11、0.69±0.13,F=264.577,P<0.001),SLFN11低于癌旁组织和对照组(0.78±0.12 vs.0.96±0.17、0.98±0.15,F=46.396,P<0.001)。HCC组NOC2L表达与病理分级、原发肿瘤T分期、转移淋巴结数、远处转移及TNM分期均呈正相关关系(均r_(s)>0,P<0.05),SLFN11表达与上述项目均呈负相关关系(均r_(s)<0,P<0.05)。SLFN11联合NOC2L检测预测肝癌预后不良的效能高于NOC2L、SLFN11单独预测(P<0.05)。NOC2L≥1.26、SLFN11≤0.78为肝癌预后不良的独立危险因素(P<0.05)。NOC2L≥1.26、SLFN11≤0.78患者中位生存期低于NOC2L<1.26或SLFN11>0.78的患者(log-rankχ^(2)=14.618,P<0.001)。结论 肝癌NOC2L和SLFN11表达可为肝癌病情及预后评估提供客观证据,两者联合可显著提高预测病情及预后的价值。Objective NOC2L and SLFN11 are closely related to the pathogenesis of malignant tumors.The clinical value of NOC2L combined with SLFN11 detection in liver cancer was studied.Methods The expression of NOC2L and SLFN11 was detected in 95 patients with liver cancer(HCC group)and 51 patients with benign liver diseases(control group)treated in Yiwu Central Hospital from January 2020 to December 2021,and the relationship with prognosis and survival was analyzed.Results NOC2L in tumor tissue of HCC group was higher than that in adjacent tissue and control group(1.26±0.25 vs.0.72±0.11,0.69±0.13,F=264.577,P<0.001),while SLFN11 was lower than that in adjacent tissue and control group(0.78±0.12 vs.0.96±0.17,0.98±0.15,F=46.396,P<0.001).In the HCC group,NOC2L expression was positively correlated with pathological grade,primary tumor T stage,number of metastatic lymph nodes,distant metastasis,and TNM stage(all r_(s)>0,P<0.05),while SLFN11 expression was negatively correlated(all r_(s)<0,P<0.05).The efficacy of SLFN11 combined with NOC2L detection in predicting poor prognosis of liver cancer was higher than that of NOC2L and SLFN11 alone(P<0.05).NOC2L≥1.26 and SLFN11≤0.78 were independent risk factors for poor prognosis of liver cancer(P<0.05).The median survival of patients with NOC2L≥1.26 and SLFN11≤0.78 was lower than that of patients with NOC2L<1.26 or SLFN11>0.78(log-rankχ^(2)=14.618,P<0.001).Conclusion The expression of NOC2L and SLFN11 in liver cancer can provide objective evidence for the evaluation of liver cancer disease and prognosis.The combination of the two can significantly improve the value of predicting disease and prognosis.

关 键 词：肝癌 NOC2类核仁相关转录抑制因子 Schlafen家族成员11 

分 类 号：R735.7[医药卫生—肿瘤]